Subtype
Liver Neoplasm
CI-CAN-00001077Explore in graph →
Non-malignant930 active trials14 approved drugs17 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001077Explore in graph →
Clinical trials
4,331 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05199285 | A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab | terminated | Phase 2 | 15 | Academic and Community Cancer Research UnitedOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT05564403 | Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) | active not recruiting | Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2026 |
| clinicaltrials |
| NCT06822842 | Accurate Diagnosis and Grading of Pediatric Solid Tumors Based on Pathological Large Models | completed | — | 1,229 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07381634 | The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities | recruiting | Phase 2 | 134 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07745153 | Novel Abdominal Compression Positioning Technique for Respiratory Motion Management in Liver Tumors | completed | — | 120 | Southern Medical University, ChinaOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07745790 | Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer | not yet recruiting | Phase 2 | 20 | Ruijin HospitalOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT04320888 | Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 3 | Aug 3, 2026 | clinicaltrials |
| NCT05285358 | Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases | recruiting | Phase 1 | 12 | City of Hope Medical CenterOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT05443087 | TARGETed Therapy Drug MONITOring in DIGestive Oncology(TARGETMONITO) | recruiting | N/A | 330 | UNICANCEROTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06877637 | On-treatment Surveillance of Tumor Evolution and Response to Systemic Treatment in Bile Duct and Liver Cancer(BILLIONSTARS) | recruiting | — | 150 | Region SkaneOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07179900 | Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma | recruiting | Phase 2 | 60 | Hebei Medical University Fourth HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07741903 | Development of a Risk Prediction Model for Immune-Targeted Therapy-Related Diarrhea in Patients With Hepatocellular Carcinoma Based on TCM Constitutional Types: A Prospective Cohort Study | not yet recruiting | — | 500 | Affiliated Hospital of Chengde Medical UniversityOTHER | 0 | Aug 3, 2026 | clinicaltrials |
| NCT03383458 | A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation(CheckMate 9DX) | active not recruiting | Phase 3 | 545 | Bristol-Myers SquibbINDUSTRY | 25 | Jul 31, 2026 | clinicaltrials |
| NCT04912765 | Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC | recruiting | Phase 2 | 60 | National Cancer Centre, SingaporeOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06458998 | Getting To Implementation: Improving Cancer Screening for Veterans(GTI) | enrolling by invitation | N/A | 30,300 | University of PittsburghOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07268131 | TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria(TITAN-HCC) | recruiting | N/A | 30 | Fudan UniversityOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07419841 | A Phase 1 Study of the Safety and Tolerability of CTX-10726 | recruiting | Phase 1 | 70 | Compass TherapeuticsINDUSTRY | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04194775 | A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma | active not recruiting | Phase 3 | 534 | CStone PharmaceuticalsINDUSTRY | 6 | Jul 30, 2026 | clinicaltrials |
| NCT04337177 | Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors | active not recruiting | Phase 1 | 20 | Valent Technologies, LLCINDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03695250 | BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer | terminated | Phase 1 / Phase 2 | 8 | Edward KimOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT04712643 | A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma | active not recruiting | Phase 3 | 342 | Hoffmann-La RocheINDUSTRY | 2 | Jul 29, 2026 | clinicaltrials |
| NCT05621499 | HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma | active not recruiting | N/A | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07732504 | AI-Guided Surveillance and Curative Salvage of Recurrence After Hepatocellular Carcinoma Resection or Ablation(HCC-AI-RECLAIM) | not yet recruiting | N/A | 2,000 | Tongji HospitalOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07732686 | Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry | not yet recruiting | — | 2,000 | University of OklahomaOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07734857 | Peripheral Blood Biomarkers and Response to Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma | not yet recruiting | — | 100 | Shanghai Zhongshan HospitalOTHER | 0 | Jul 29, 2026 | clinicaltrials |
| NCT06710223 | Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab | active not recruiting | Phase 1 | 16 | University of California, San DiegoOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07059494 | Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant | recruiting | Phase 4 | 40 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07479485 | MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II) | recruiting | Phase 1 / Phase 2 | 160 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07719933 | Intraoperative Continuous Terlipressin Infusion is Associated With Reduced Severe Postoperative Complications After Laparoscopic Hepatectomy: a Prospective Propensity Score-matched Cohort Study | completed | — | 161 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT03298451 | Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma(HIMALAYA) | active not recruiting | Phase 3 | 1,324 | AstraZenecaINDUSTRY | 17 | Jul 27, 2026 | clinicaltrials |
| NCT07724951 | The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study | not yet recruiting | — | 400 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07729592 | Dapagliflozin Add-on in Unresectable HCC With Metabolic Syndrome | not yet recruiting | Phase 2 | 44 | Sun Yat-sen UniversityOTHER | 0 | Jul 27, 2026 | clinicaltrials |
| NCT07729618 | AI-Guided First-Line Immunotherapy Selection in Unresectable Hepatocellular Carcinoma(HCC-AI-SELECT) | not yet recruiting | N/A | 1,800 | Tongji HospitalOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT03155620 | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | active not recruiting | Phase 2 | 1,377 | National Cancer Institute (NCI)NIH | 4 | Jul 24, 2026 | clinicaltrials |
| NCT05117957 | Efficacy and Safety of Sorafenib in Previously Treated Advanced Hepatocellular Carcinoma: SOPT Study | completed | Phase 2 | 50 | Bo Hyun KimOTHER_GOV | 1 | Jul 24, 2026 | clinicaltrials |
| NCT06193733 | Dendritic Cell Vaccination to Prevent Hepatocellular Carcinoma Recurrence After Liver Resection - Phase II Clinical Trial | active not recruiting | Phase 2 | 74 | Chang Gung Memorial HospitalOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07726329 | Dendritic Cell-immunotherapy for Advanced Hepatocellular Carcinoma | active not recruiting | Phase 2 | 100 | Chang Gung Memorial HospitalOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT06796114 | Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Durvalumab(PREDICT-HCC) | recruiting | N/A | 120 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT04892810 | Immunomonitoring of Interventional Radiology Procedures in the Management of Hepatocellular Carcinoma(PAI²HCC) | completed | — | 20 | University Hospital, GrenobleOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT05208762 | A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors | recruiting | Phase 1 | 714 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 11 | Jul 22, 2026 | clinicaltrials |
| NCT04930315 | SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma(CAPT) | completed | Phase 2 | 78 | Zhejiang UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05377827 | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies | suspended | Phase 1 | 6 | Washington University School of MedicineOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05492136 | Unravelling the Impact of Radiofrecuency in Liver Surgery: the Key to Decrease Local Recurrence?(LIVERaTION) | recruiting | N/A | 720 | Hospital del MarOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07690683 | Patients With Hepatocellular Carcinoma (HCC)(FORCE) | not yet recruiting | N/A | 52 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07716345 | Inter-Individual Tumor Heterogeneity on 3D-MRE for Predicting Response to Conversion Therapy in Liver Cancer | not yet recruiting | — | 100 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 0 | Jul 21, 2026 | clinicaltrials |
| NCT04545957 | Jump: MR Simulation For Radiation Therapy Master Protocol(JUMP) | recruiting | N/A | 86 | Brigham and Women's HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT05128032 | Pressure-enabled Delivery in Radioembolization (TriNav Study)(PEDIR) | completed | N/A | 29 | Massachusetts General HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 4, 2026source: clinicaltrials